Ironwood Pharmaceuticals IRWD
$4.70 −$0.01 (-0.21%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $4.60 -2.13%
Open$4.66
Prev close$4.71
Day range$4.65 – $4.87
Volume3.02M
Market cap$778.09M
P/E (TTM)5.2
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$133.04M+9.0% YoY
Operating profit$93.13M+19.9% YoY
Net profit$59.84M+49.3% YoY
Diluted EPS$0.36+56.5% YoY
Free cash flow$67.40M+41.7% YoY
Operating cash flow$67.40M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Operating margin62.8%
Net margin37.4%
Return on assets43.6%
Current ratio6.51
Liabilities / assets133.4%
Cash & investments$86.38M
Total debt$332.91M
Net cash (debt)-$246.53M
Free cash flow / sales51.3%
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $133.04M | $113.04M | $106.51M | $296.15M | $47.71M |
| Total Operating Revenue | $133.04M | $113.04M | $106.51M | $296.15M | $47.71M |
| Operating Expense | $39.91M | $33.73M | $33.97M | $177.39M | $41.16M |
| Selling and Admin Expenses | $11.55M | $11.31M | $12.03M | $82.26M | $19.29M |
| Research & Development | $28.35M | $22.42M | $21.94M | $95.14M | $21.86M |
| Operating Profit | $93.13M | $79.31M | $72.53M | $118.76M | $6.55M |
| Net Non-Operating Interest Income (Expense) | -$5.58M | -$5.62M | -$7.44M | -$28.67M | -$6.43M |
| Non-Operating Interest Income | $619,000.00 | $1.59M | $1.70M | $4.08M | $1.46M |
| Non-Operating Interest Expense | $6.20M | $7.20M | $8.97M | $32.75M | $7.89M |
| Other Income (Expense) | $41,000.00 | $42,000.00 | $82,000.00 | -$20.06M | $329,000.00 |
| Special Income (Charges) | $0.00 | $0.00 | $40,000.00 | -$20.26M | $252,000.00 |
| -Less:Restructuring and Mergern & Acquisition | $0.00 | $0.00 | -$40,000.00 | $20.26M | -$252,000.00 |
| Other Non-Operating Income (Expenses) | $41,000.00 | $42,000.00 | $42,000.00 | $193,000.00 | $77,000.00 |
| Pretax Profit | $87.60M | $73.73M | $65.17M | $70.03M | $455,000.00 |
| Tax | $27.76M | $22.44M | $24.40M | $46.01M | $2.73M |
| Net Profit | $59.84M | $51.29M | $40.77M | $24.02M | -$2.28M |
| Profit from Continuing Operations | $59.84M | $51.29M | $40.77M | $24.02M | -$2.28M |
| Net Income to Parent Company | $59.84M | $51.29M | $40.77M | $24.02M | -$2.28M |
| Net Income to Common Stockholders | $59.84M | $51.29M | $40.77M | $24.02M | -$2.28M |
| Basic EPS | $0.36 | $0.31 | $0.25 | $0.15 | -$0.01 |
| Diluted EPS | $0.36 | $0.31 | $0.24 | $0.15 | -$0.01 |
| Total Other Finance Costs | – | – | $175,000.00 | – | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $290.59M | $285.13M | $434.57M | $396.90M | $396.90M |
| Total Current Assets | $225.99M | $199.20M | $332.29M | $274.18M | $274.18M |
| Cash and Cash Equivalents & Short-Term Investments | $86.38M | $79.13M | $220.47M | $215.46M | $215.46M |
| -Cash and Cash Equivalents | $86.38M | $79.13M | $220.47M | $215.46M | $215.46M |
| Receivables | $132.72M | $112.73M | $105.84M | $46.75M | $46.75M |
| -Accounts Receivable | $132.72M | $112.73M | $105.84M | $46.75M | $46.75M |
| Other Current Assets | $6.90M | $7.34M | $5.98M | $11.98M | $11.98M |
| Total Non-Current Assets | $64.60M | $85.93M | $102.27M | $122.72M | $122.72M |
| Net PPE | $10.64M | $11.36M | $12.06M | $12.75M | $12.75M |
| -Gross PPE | $10.64M | $11.36M | $12.06M | $20.75M | $20.75M |
| Goodwill and Other Intangible Assets | $1.43M | $1.63M | $1.84M | $2.04M | $2.04M |
| -Other Intangible Assets | $1.43M | $1.63M | $1.84M | $2.04M | $2.04M |
| Non-Current Deferred Assets | $48.94M | $69.06M | $84.24M | $103.43M | $103.43M |
| Other Non-Current Assets | $3.60M | $3.87M | $4.14M | $4.50M | $4.50M |
| Total Liabilities | $387.79M | $446.97M | $651.71M | $658.74M | $658.74M |
| Total Current Liabilities | $34.73M | $32.85M | $236.31M | $242.22M | $242.22M |
| Payables | $5.01M | $5.19M | $7.13M | $3.83M | $3.83M |
| -Accounts Payable | $3.62M | $911,000.00 | $3.24M | $2.90M | $2.90M |
| -Total Tax Payable | $1.39M | $4.28M | $3.89M | $927,000.00 | $927,000.00 |
| Current Accrued Expenses | $12.81M | $12.12M | $12.07M | $13.36M | $13.36M |
| Short-Term Debt and Capital Lease Obligation | $3.30M | $3.29M | $203.12M | $202.93M | $202.93M |
| -Current Capital Lease Obligation | $3.30M | $3.29M | $3.27M | $3.25M | $3.25M |
| Current Deferred Liabilities | $1.26M | $1.25M | $1.47M | $1.11M | $1.11M |
| Other Current Liabilities | $2.41M | $3.52M | $5.98M | $9.41M | $9.41M |
| Total Non-Current Liabilities | $353.05M | $414.12M | $415.40M | $416.52M | $416.52M |
| Long Term Debt and Capital Lease Obligation | $332.91M | $393.58M | $394.23M | $394.87M | $394.87M |
| -Long Term Debt | $325.00M | $385.00M | $385.00M | $385.00M | $385.00M |
| -Long Term Capital Lease Obligation | $7.91M | $8.58M | $9.23M | $9.87M | $9.87M |
| Other Non-Current Liabilities | $20.14M | $20.54M | $21.17M | $21.65M | $21.65M |
| Total Equity | -$97.19M | -$161.84M | -$217.14M | -$261.84M | -$261.84M |
| Stockholders' Equity | -$97.19M | -$161.84M | -$217.14M | -$261.84M | -$261.84M |
| Capital Stock | $166,000.00 | $165,000.00 | $165,000.00 | $163,000.00 | $163,000.00 |
| -Common Stock | $166,000.00 | $165,000.00 | $165,000.00 | $163,000.00 | $163,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B |
| Retained Earnings | -$1.52B | -$1.58B | -$1.63B | -$1.67B | -$1.67B |
| Gains/Losses Not Affecting Retained Earnings | $196,000.00 | -$324,000.00 | -$795,000.00 | -$1.06M | -$1.06M |
| -Current Debt | – | – | $199.86M | $199.68M | $199.68M |
| -Accumulated Depreciation | – | – | – | -$8.01M | -$8.01M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $67.40M | $58.28M | $5.12M | $127.04M | $74.58M |
| Net cash flow from continuing operations | $67.40M | $58.28M | $5.12M | $127.04M | $74.58M |
| Net Income from Continuing Operations | $59.84M | $51.29M | $40.77M | $24.02M | -$2.28M |
| Depreciation & Depletion & Amortization | $459,000.00 | $457,000.00 | $443,000.00 | $1.88M | $460,000.00 |
| Deferred Tax | $20.13M | $15.17M | $19.20M | $40.80M | -$1.75M |
| Other Non-Cash Items | $707,000.00 | $842,000.00 | $863,000.00 | $1.67M | -$835,000.00 |
| Change in Working Capital | -$18.02M | -$12.72M | -$59.81M | $41.34M | $75.15M |
| -Change in Receivables | -$19.99M | -$6.89M | -$59.10M | $35.15M | $73.62M |
| -Change in Prepaid Assets | $387,000.00 | -$1.42M | $6.00M | $367,000.00 | $1.09M |
| -Change in Payables and Accrued Expense | $2.41M | -$3.49M | -$5.99M | $2.10M | -$592,000.00 |
| -Change in Other Current Assets | $28,000.00 | $17,000.00 | $121,000.00 | $2.14M | $1.79M |
| -Change in Other Current Liabilities | -$860,000.00 | -$944,000.00 | -$840,000.00 | $1.59M | -$753,000.00 |
| Net cash flow from investing | $0.00 | $0.00 | $0.00 | -$34,000.00 | $1,000.00 |
| Net Cash Flow from Continuing Investing Activities | $0.00 | $0.00 | $0.00 | -$34,000.00 | $1,000.00 |
| Net PPE Purchase and Sale | $0.00 | $0.00 | $0.00 | -$34,000.00 | $1,000.00 |
| Financing Cash Flow | -$60.00M | -$199.70M | $0.00 | $216,000.00 | $122,000.00 |
| Net Cash Flow from Continuing Financing Activities | -$60.00M | -$199.70M | $0.00 | $216,000.00 | $122,000.00 |
| Net Issuance Payments Of Debt | -$60.00M | – | – | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $0.00 | $303,000.00 | $0.00 | $216,000.00 | $122,000.00 |
| Ending Cash Balance | $86.38M | $79.13M | $220.47M | $215.46M | $215.46M |
| Net Change in Cash | $7.40M | -$141.42M | $5.12M | $127.23M | $74.70M |
| Beginning Cash Balance | $79.13M | $220.47M | $215.46M | $88.56M | $140.41M |
| Effect of Exchange Rate Changes | -$152,000.00 | $77,000.00 | -$106,000.00 | -$329,000.00 | $351,000.00 |
| Free Cash Flow | $67.40M | $58.28M | $5.12M | $127.01M | $74.58M |
| Gain/Loss from Continuing Operations | – | – | – | $89,000.00 | -$3,000.00 |
No comments yet — be the first to weigh in on IRWD.
Sign in to join the discussion.